s
EADV Congress 2024: Semaglutide improves outcomes for obese patients with common skin condition, new study shows
25-09-2024, 09:12
A pioneering study, presented today at the EADV Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity. AMSTERDAM, Sept. 25, 2024 /PRNewswire/ — This is the first study to explore the use of semaglutide for HS, marking a critical milestone in the […] L'articolo EADV Congress 2024: Semaglutide improves outcomes for obese patients with common skin condition, new study shows proviene da La Ragione.
CONTINUA A LEGGERE
6
0
0
Guarda anche
La Ragione
Ieri, 21:43
Juric “Non abbassiamo guardia, con l’Elfsborg sarà una battaglia”
La Ragione
Ieri, 21:43
Il Presidente Mattarella riceve sei nuovi ambasciatori
La Ragione
Ieri, 21:18
L’azione di Israele
La Ragione
Ieri, 20:43
Malagò “Grati a Poste italiane, danno un valore aggiunto”
La Ragione
Ieri, 19:48